Authors
Andrea Bezjak, Dongsheng Tu, Lesley Seymour, Gary Clark, Aleksandra Trajkovic, Mauro Zukin, Joseph Ayoub, Sergio Lago, Ronaldo de Albuquerque Ribeiro, Alexandra Gerogianni, Arnold Cyjon, Jonathan Noble, Francis Laberge, Raymond Tsz-Tong Chan, David Fenton, Joachim von Pawel, Martin Reck, Frances A Shepherd
Publication date
2006/8/20
Journal
Journal of clinical oncology
Volume
24
Issue
24
Pages
3831-3837
Publisher
American Society of Clinical Oncology
Description
Purpose
This report describes the quality of life (QOL) findings of a randomized placebo controlled study of erlotinib, an epidermal growth factor receptor inhibitor, in patients with non–small-cell lung cancer (NSCLC).
Patients and Methods
This double-blind phase III trial randomly assigned 731 patients with NSCLC who had progressed after prior chemotherapy to erlotinib 150 mg daily or placebo, with survival as the primary study outcome. QOL was assessed by European Organisation for Research and Treatment of Cancer QLQ-C30 and the lung cancer module QLQ-LC13. The primary end points for QOL analysis were time to deterioration of three common lung cancer symptoms: cough, dyspnea, and pain.
Results
Survival was significantly longer (hazard ratio, 0.70; P < .0001) in the erlotinib arm. Compliance with QOL was 87% at baseline and more than 70% during …
Total citations
Scholar articles
A Bezjak, D Tu, L Seymour, G Clark, A Trajkovic… - Journal of clinical oncology, 2006